NEW YORK--(BUSINESS WIRE)--OverT Bio, an NYC-based cell therapy company, today announced that it has been awarded a $120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM. This grant will support OverT Bio’s ongoing development efforts that will lead to next generation cell therapies for solid tumors, based on innovative data-driven discovery platforms OverTargetTM and OverTCRTM..

。这项拨款将支持OverT Bio正在进行的开发工作，该工作将基于创新的数据驱动发现平台OverTargetTM和OverTCRTM，为实体瘤开发下一代细胞疗法。。

The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant no-cost support allowing for expeditious optimization of cell manufacturing processes.

G-Rex赠款是ScaleReady 2000万美元赠款计划的一部分，该计划旨在推进细胞和基因治疗（CGT）的开发和制造。G-Rex赠款计划为接受者提供了大量无成本支持，可以快速优化细胞制造过程。

“We are pleased to receive ScaleReady’s support and their recognition of the potentially high impact our technology has to advance our shared mission of bringing new life-saving therapeutics to cancer patients,” stated Mat Legut, PhD, CEO of OverT Bio. “This grant, including its access to newly developed GMP closed system products and ScaleReady’s expertise, will help us accelerate the development of our products in a way that will ensure future scalability and cost-effectiveness of these potential medicines.”.

“我们很高兴得到ScaleReady的支持，他们认识到我们的技术对推动我们为癌症患者带来新的挽救生命疗法的共同使命具有潜在的巨大影响，”OverT Bio首席执行官Mat Legut博士表示。“这笔赠款，包括其获得新开发的GMP封闭系统产品和ScaleReady的专业知识，将有助于我们加速产品的开发，以确保这些潜在药物的未来可扩展性和成本效益。”。

“Our support of OverT Bio is yet another example of how our G-Rex Grant Program is being used to facilitate advancement of the field of cell and gene-modified cell therapy,” said Josh Ludwig, Commercial Director of ScaleReady. “The G-Rex Grant Program augments ScaleReady’s primary purpose of providing every CGT company with the ability to save time and money while building a strong value proposition for continued investment on favorable terms.”.

ScaleReady商业总监Josh Ludwig说：“我们对OverT Bio的支持是我们的G-Rex赠款计划如何被用于促进细胞和基因修饰细胞治疗领域进步的另一个例子。”。“G-Rex赠款计划增强了ScaleReady的主要目的，即为每家CGT公司提供节省时间和金钱的能力，同时为以优惠条件继续投资建立强大的价值主张。”。

About OverT Bio

关于公开生物

OverT Bio, Inc., is a New York based biotechnology company developing effective and safe cellular therapies for solid tumors. Harnessing innovative pooled functional screening and synthetic genomics platforms (OverTargetTM and OverTCRTM), OverT Bio is uncovering new therapeutic targets and genetic enhancements in an unbiased, data-driven manner to deliver breakthrough medicines to cancer patients underserved by the standard of care.

OverT Bio，Inc.是一家总部位于纽约的生物技术公司，正在开发针对实体瘤的有效且安全的细胞疗法。利用创新的汇集功能筛选和合成基因组学平台（OverTargetTM和OverTCRTM），OverT Bio正在以无偏见，数据驱动的方式揭示新的治疗靶点和基因增强，为未得到标准治疗的癌症患者提供突破性药物。

For more information, please visit: www.overt.bio..

欲了解更多信息，请访问：www.overt.bio。。

About ScaleReady™

关于ScaleReady™

ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs.

ScaleReady为细胞和基因修饰细胞疗法（CGT）领域提供了一个以G-Rex为中心的制造平台，使世界上最实用、灵活、可扩展和负担得起的CGT药物产品开发和制造成为可能。G-Rex制造平台目前被800多家快速增长的组织使用，目前正在为大约50%的CGT临床试验以及5种商业批准的CGT药物生产药物。

CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com..

依靠ScaleReady专业知识的广度和范围的CGT实体有望在CGT商业化的道路上节省数年的时间和数百万美元。有关ScaleReady G-Rex®赠款计划的更多信息，请联系info@scaleready.com..

About Wilson Wolf Manufacturing Corporation

关于Wilson Wolf制造公司

Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.

威尔逊·沃尔夫（www.wilsonwolf.com）致力于简化细胞和基因修饰细胞（CGT）治疗研究、工艺开发和制造。这是通过其可扩展的G-Rex®技术实现的，该技术在全球范围内用于CGT应用，从基础研究到商业药物生产。

Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time..

威尔逊·沃尔夫（Wilson Wolf）的使命是为癌症患者创造希望，一次一个G-Rex®设备。。

About Bio-Techne Corporation

关于Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing.

Bio-Techne Corporation（NASDAQ:TECH）是一家全球生命科学公司，为研究和临床诊断界提供创新工具和生物活性试剂。Bio-Techne与Wilson Wolf合作，正在开发专门为G-Rex®生物反应器量身定制的培养基和细胞因子等产品，包括适合高通量封闭系统制造的容器中正确大小的试剂量。

For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube..

有关Bio-Techne及其品牌的更多信息，请访问https://www.bio-techne.com或者在社交媒体上关注该公司：Facebook、LinkedIn、Twitter或YouTube。。

About CellReady™

关于CellReady™

CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies..

CellReady是世界上第一个也是唯一一个以G-Rex为中心的合同开发和制造组织（CDMO），专门从事基于G-Rex的细胞和基因修饰细胞疗法的开发和制造。该公司提供广泛的服务，以支持这些疗法的开发和商业化。。

CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.

CellReady的使命是为癌症患者创造希望，一次一个G-Rex®过程。